Efficacy and safety of ranibizumab 0.5 mg treat and extend versus monthly regimen in patients with neovascular age-related macular degeneration: 12-month results from the TREND study.

被引：0
|
作者：
Silva, Rufino [1 ,2 ,3 ]
Larsen, Michael [4 ,5 ]
Feller, Chrystel [6 ]
Macfadden, Wayne [6 ]
机构：
[1] Univ Coimbra, Fac Med, Dept Ophthalmol, Coimbra, Portugal
[2] CHUC, Coimbra, Portugal
[3] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal
[4] Univ Copenhagen, Rigshosp, Dept Ophthalmol, Copenhagen, Denmark
[5] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark
[6] Novartis Pharma AG, Dept Ophthalmol, Basel, Switzerland
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2017年 / 58卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
416
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration Results with Ranibizumab from the TREND Study
    Silva, Rufino
    Berta, Andras
    Larsen, Michael
    Macfadden, Wayne
    Feller, Chrystel
    Mones, Jordi
    [J]. OPHTHALMOLOGY, 2018, 125 (01) : 57 - 65
  • [2] Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab
    Abdelfattah, Nizar S.
    Al-Sheikh, Mayss
    Pitetta, Sean
    Mousa, Ahmed
    Sadda, SriniVas R.
    Wykoff, Charles C.
    [J]. OPHTHALMOLOGY, 2017, 124 (02) : 215 - 223
  • [3] Ranibizumab 0.5 mg for Neovascular Age-Related Macular Degeneration: Monthly versus as Needed Dosing in the DRAGON Study
    Li, Xiaoxin
    Zhu, Aileen
    Egger, Anna
    Song, Yanping
    Zhang, Junjun
    Dong, Fangtian
    Xu, Xun
    [J]. OPHTHALMOLOGICA, 2016, 236 : 20 - 21
  • [4] Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
    Busbee, Brandon G.
    Ho, Allen C.
    Brown, David M.
    Heier, Jeffrey S.
    Suner, Ivan J.
    Li, Zhengrong
    Rubio, Roman G.
    Lai, Phillip
    [J]. OPHTHALMOLOGY, 2013, 120 (05) : 1046 - 1056
  • [5] Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study
    Hatz, Katja
    Prunte, Christian
    [J]. ACTA OPHTHALMOLOGICA, 2017, 95 (01) : E67 - E72
  • [6] A 12-MONTH PROSPECTIVE TRIAL OF INJECT AND EXTEND REGIMEN FOR RANIBIZUMAB TREATMENT OF AGE-RELATED MACULAR DEGENERATION
    Toalster, Nicholas
    Russell, Matthew
    Ng, Paul
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2013, 33 (07): : 1351 - 1358
  • [7] Bimonthly, treat-and-extend and as-needed ranibizumab in naive neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study
    Galvez, Maria Isabel Lopez
    Barquet, Lluis Arias
    Figueroa, Marta S.
    Garcia-Layana, Alfredo
    Moreno, Jose M. Ruiz
    [J]. ACTA OPHTHALMOLOGICA, 2020, 98 (07) : E820 - E829
  • [8] Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study
    Schmidt-Erfurth, Ursula
    Eldem, Bora
    Guymer, Robyn
    Korobelnik, Jean-Francois
    Schlingemann, Reinier O.
    Axer-Siegel, Ruth
    Wiedemann, Peter
    Simader, Christian
    Gekkieva, Margarita
    Weichselberger, Andreas
    [J]. OPHTHALMOLOGY, 2011, 118 (05) : 831 - 839
  • [9] Safety and tolerability of ranibizumab in uni/bilateral neovascular age-related macular degeneration: 12-month TWEYEs study
    Bandello, Francesco
    Staurenghi, Giovanni
    Ricci, Federico
    Midena, Edoardo
    Viola, Francesco
    Lupieri Sinibaldi, Tommaso
    Colombo, Laura
    Peruzzi, Elena
    Bassanini, Stefania
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2020, 104 (01) : 64 - 73
  • [10] Twenty-four-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration
    Ho, Allen C.
    Busbee, Brandon G.
    Regillo, Carl D.
    Wieland, Mark R.
    Van Everen, Sherri A.
    Li, Zhengrong
    Rubio, Roman G.
    Lai, Phillip
    [J]. OPHTHALMOLOGY, 2014, 121 (11) : 2181 - 2192
12345